Photodynamic Therapy Alone Versus Combined With Intravitreal Bevacizumab for Age-related Macular Degeneration

• Status: Completed
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare 12-month results of two single initial treatments-photodynamic therapy with verteporfin alone and this therapy combined with intravitreal bevacizumab-for neovascular age-related macular degeneration, not including patients with polypoidal choroidal vasculopathy who were presumed to have age-related macular degeneration.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kumamoto University
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• choroidal neovascularization caused by age-related macula degeneration

• no previous treatment

• a follow-up at least 12 months

• a baseline visual acuity ranging from a letter score of 0 to 70 on the Early Treatment Diabetic Retinopathy Study chart

Exclusion Criteria:

• choroidal neovascularization caused by other eye diseases

• ocular surgery within the past 3 mouths

• history of uveitis

• intraocular pressure higher than 25 mmHg, or glaucoma

• history of systemic or ocular thromboembolic events.